Skip to content

Arvinas ARVN EBITDA margin

EBITDA margin at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-427.3%+42.6pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-681.6%+642pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-325.8%
Immunome logo
ImmunomeIMNM
-5,886.7%-11,897pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-10,195.5%-4,935pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-164.8%-51.5pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's EBITDA margin?
Arvinas (ARVN) reported EBITDA margin of -280.4% in Q1 2026.
How has Arvinas's EBITDA margin changed year-over-year?
Arvinas's EBITDA margin decreased by 1208.3% year-over-year, from -21.4% to -280.4%.
What is the long-term trend for Arvinas's EBITDA margin?
Over 4 years (2020 to 2025), Arvinas's EBITDA margin has grown at a -44.2% compound annual growth rate (CAGR), from -454.1% to -44%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.